Advertisement

Topics

Human medicines European public assessment report (EPAR): Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune), pandemic influenza vaccine (H5N1) (live attenuated, nasal), Influenza, Human, Date of authorisati

07:00 EDT 10 May 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune), pandemic influenza vaccine (H5N1) (live attenuated, nasal), Influenza, Human, Date of authorisation: 20/05/2016, Revision: 3, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune), pandemic influenza vaccine (H5N1) (live attenuated, nasal), Influenza, Human, Date of authorisati

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune), pandemic influenza vaccine (H5N1) (live attenuated, nasal), Influenza, Human, Date of authorisati"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...